Skip to main content

Advertisement

SpringerLink
Log in

CAP, a new human suspension cell line for influenza virus production

  • Biotechnological Products and Process Engineering
  • Published:
Applied Microbiology and Biotechnology Aims and scope Submit manuscript

Abstract

Forced by major drawbacks of egg-based influenza virus production, several studies focused on the establishment and optimization of cell-based production systems. Among numerous possible host cell lines from duck, monkey, canine, chicken, mouse, and human origin, only a few will meet regulatory requirements, accomplish industrial standards, and result in high virus titers. From primary virus isolation up to large-scale manufacturing of human vaccines, however, the most logical choice seems to be the use of human cell lines. For this reason, we evaluated the recently established CAP cell line derived from human amniocytes for its potential in influenza virus production in suspension culture in small scale shaker flask and stirred tank bioreactor experiments. Different human and animal influenza viruses could be adapted to produce hemagglutination (HA) titers of at least 2.0 log10 HA units/100 μL without further process optimization. Adjusting trypsin activity as well as infection conditions (multiplicity of infection, infection medium) resulted in HA titers of up to 3.2 log10 HA units/100 μL and maximum cell-specific virus productivities of 6,400 virions/cell (for human influenza A/PR/8/34 as a reference). Surface membrane expression of sialyloligosaccharides as well as HA N-glycosylation patterns were characterized. Overall, experimental results clearly demonstrate the potential of CAP cells for achieving high virus yields for different influenza strains and the option to introduce a highly attractive fully characterized human cell line compliant with regulatory and industrial requirements as an alternative for influenza virus vaccine production.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  • Aggarwal K, Jing F, Maranga L, Liu J (2011) Bioprocess optimization for cell culture based influenza vaccine production. Vaccine 29(17):3320–3328. doi:10.1016/j.vaccine.2011.01.081

    Article  CAS  Google Scholar 

  • Chu C, Lugovtsev V, Golding H, Betenbaugh M, Shiloach J (2009) Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production. Proc Natl Acad Sci U S A 106(35):14802–14807. doi:10.1073/pnas.0905912106

    Article  CAS  Google Scholar 

  • Chu C, Lugovtsev V, Lewis A, Betenbaugh M, Shiloach J (2010) Production and antigenic properties of influenza virus from suspension MDCK-siat7e cells in a bench-scale bioreactor. Vaccine 28(44):7193–7201. doi:10.1016/j.vaccine.2010.08.059

    Article  CAS  Google Scholar 

  • Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC (1998) New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9(13):1909–1917. doi:10.1089/hum.1998.9.13-1909

    Article  CAS  Google Scholar 

  • Gambaryan AS, Marinina VP, Tuzikov AB, Bovin NV, Rudneva IA, Sinitsyn BV, Shilov AA, Matrosovich MN (1998) Effects of host-dependent glycosylation of hemagglutinin on receptor-binding properties on H1N1 human influenza A virus grown in MDCK cells and in embryonated eggs. Virology 247(2):170–177

    Article  CAS  Google Scholar 

  • Genzel Y, Reichl U (2007) Vaccine production - state of the art and future needs in upstream processing. In: Pörtner R (ed) Methods in biotechnology: animal cell biotechnology—methods and protocols. Humana Press Inc., Totowa, pp 457–473

    Google Scholar 

  • Genzel Y, Reichl U (2009) Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines 8(12):1681–1692. doi:10.1586/erv.09.128

    Article  CAS  Google Scholar 

  • Genzel Y, Behrendt I, Konig S, Sann H, Reichl U (2004) Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture. Vaccine 22(17–18):2202–2208. doi:10.1016/j.vaccine.2003.11.041

    Article  CAS  Google Scholar 

  • Genzel Y, Fischer M, Reichl U (2006) Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture. Vaccine 24(16):3261–3272. doi:10.1016/j.vaccine.2006.01.019

    Article  CAS  Google Scholar 

  • Genzel Y, Dietzsch C, Rapp E, Schwarzer J, Reichl U (2010) MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation. Appl Microbiol Biotechnol 88(2):461–475. doi:10.1007/s00253-010-2742-9

    Article  CAS  Google Scholar 

  • George M, Farooq M, Dang T, Cortes B, Liu J, Maranga L (2010) Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process. Biotechnol Bioeng 106(6):906–917. doi:10.1002/bit.22753

    Article  CAS  Google Scholar 

  • Govorkova EA, Kaverin NV, Gubareva LV, Meignier B, Webster RG (1995) Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero). J Infect Dis 172(1):250–253

    Article  CAS  Google Scholar 

  • Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36(1):59–74

    Article  CAS  Google Scholar 

  • Gregersen JP, Schmitt HJ, Trusheim H, Broker M (2011) Safety of MDCK cell culture-based influenza vaccines. Future Microbiol 6(2):143–152. doi:10.2217/fmb.10.161

    Article  Google Scholar 

  • Jordan I, Vos A, Beilfuss S, Neubert A, Breul S, Sandig V (2009) An avian cell line designed for production of highly attenuated viruses. Vaccine 27(5):748–756. doi:10.1016/j.vaccine.2008.11.066

    Article  CAS  Google Scholar 

  • Kalbfuss B, Knochlein A, Krober T, Reichl U (2008) Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity. Biologicals 36(3):145–161

    Article  CAS  Google Scholar 

  • Kaverin NV, Webster RG (1995) Impairment of multicycle influenza virus growth in Vero (WHO) cells by loss of trypsin activity. J Virol 69(4):2700–2703

    CAS  Google Scholar 

  • Le Ru A, Jacob D, Transfiguracion J, Ansorge S, Henry O, Kamen AA (2010) Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine 28(21):3661–3671. doi:10.1016/j.vaccine.2010.03.029

    Article  Google Scholar 

  • Lohr V, Rath A, Genzel Y, Jordan I, Sandig V, Reichl U (2009) New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine 27(36):4975–4982. doi:10.1016/j.vaccine.2009.05.083

    Article  CAS  Google Scholar 

  • Lohr V, Genzel Y, Behrendt I, Scharfenberg K, Reichl U (2010) A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor. Vaccine 28(38):6256–6264. doi:10.1016/j.vaccine.2010.07.004

    Article  CAS  Google Scholar 

  • Mehtali M, Champion-Arnaud P, Leon A (2006) Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines WO 2006108846 (A1)

  • Nishiyama K, Sugawara K, Nouchi T, Kawano N, Soejima K, Abe S, Mizokami H (2008) Purification and cDNA cloning of a novel protease inhibitor secreted into culture supernatant by MDCK cells. Biologicals 36(2):122–133. doi:10.1016/j.biologicals.2007.07.004

    Article  CAS  Google Scholar 

  • Paillet C, Forno G, Kratje R, Etcheverrigaray M (2009) Suspension-Vero cell cultures as a platform for viral vaccine production. Vaccine 27(46):6464–6467. doi:10.1016/j.vaccine.2009.06.020

    Article  CAS  Google Scholar 

  • Paillet C, Forno G, Soldano N, Kratje R, Etcheverrigaray M (2011) Statistical optimization of influenza H1N1 production from batch cultures of suspension Vero cells (sVero). Vaccine 29(41):7212–7217. doi:10.1016/j.vaccine.2011.07.016

    Article  CAS  Google Scholar 

  • Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F (2001) The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19(17–19):2716–2721

    Article  CAS  Google Scholar 

  • Petiot E, Jacob D, Lanthier S, Lohr V, Ansorge S, Kamen AA (2011) Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture. BMC Biotechnol 11:84. doi:10.1186/1472-6750-11-84

    Article  CAS  Google Scholar 

  • Reading PC, Tate MD, Pickett DL, Brooks AG (2007) Glycosylation as a target for recognition of influenza viruses by the innate immune system. Adv Exp Med Biol 598:279–292. doi:10.1007/978-0-387-71767-8_20

    Article  Google Scholar 

  • Robertson JS, Bootman JS, Newman R, Oxford JS, Daniels RS, Webster RG, Schild GC (1987) Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology 160(1):31–37

    Article  CAS  Google Scholar 

  • Robertson JS, Nicolson C, Harvey R, Johnson R, Major D, Guilfoyle K, Roseby S, Newman R, Collin R, Wallis C, Engelhardt OG, Wood JM, Le J, Manojkumar R, Pokorny BA, Silverman J, Devis R, Bucher D, Verity E, Agius C, Camuglia S, Ong C, Rockman S, Curtis A, Schoofs P, Zoueva O, Xie H, Li X, Lin Z, Ye Z, Chen LM, O’Neill E, Balish A, Lipatov AS, Guo Z, Isakova I, Davis CT, Rivailler P, Gustin KM, Belser JA, Maines TR, Tumpey TM, Xu X, Katz JM, Klimov A, Cox NJ, Donis RO (2011) The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 29(9):1836–1843. doi:10.1016/j.vaccine.2010.12.044

    Article  CAS  Google Scholar 

  • Rödig JV, Rapp E, Djeljadini S, Lohr V, Genzel Y, Jordan I, Sandig V, Reichl U (2011a) Impact of influenza virus adaptation status on HA N-glycosylation patterns in cell culture-based vaccine production. J Carbohydr Chem 30(4–6):281–290. doi:10.1080/07328303.2011.604454

    Article  Google Scholar 

  • Rödig JV, Rapp E, Höper D, Genzel Y, Reichl U (2011b) Impact of host cell line adaptation on quasispecies composition and glycosylation of influenza A virus hemagglutinin. PLoS One 6(12):e27989. doi:10.1371/journal.pone.0027989

    Article  Google Scholar 

  • Sandig V, Jordan I (2005) Immortalized avian cell lines for virus production. WO2005/042728A2,

  • Schiedner G, Hertel S, Kochanek S (2000) Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum Gene Ther 11(15):2105–2116. doi:10.1089/104303400750001417

    Article  CAS  Google Scholar 

  • Schiedner G, Hertel S, Bialek C, Kewes H, Waschutza G, Volpers C (2008) Efficient and reproducible generation of high-expressing, stable human cell lines without need for antibiotic selection. BMC Biotechnol 8:13. doi:10.1186/1472-6750-8-13

    Article  Google Scholar 

  • Schwarzer J, Rapp E, Reichl U (2008) N-glycan analysis by CGE-LIF: profiling influenza A virus hemagglutinin N-glycosylation during vaccine production. Electrophoresis 29(20):4203–4214. doi:10.1002/elps.200800042

    Article  CAS  Google Scholar 

  • Schwarzer J, Rapp E, Hennig R, Genzel Y, Jordan I, Sandig V, Reichl U (2009) Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin. Vaccine 27(32):4325–4336. doi:10.1016/j.vaccine.2009.04.076

    Article  CAS  Google Scholar 

  • Seitz C, Frensing T, Hoper D, Kochs G, Reichl U (2010) High yields of influenza A virus in Madin-Darby canine kidney cells are promoted by an insufficient interferon-induced antiviral state. J Gen Virol 91(Pt 7):1754–1763. doi:10.1099/vir.0.020370-0

    Article  CAS  Google Scholar 

  • Seitz C, Isken B, Heynisch B, Rettkowski M, Frensing T, Reichl U (2012) Trypsin promotes efficient influenza vaccine production in MDCK cells by interfering with the antiviral host response. Appl Microbiol Biotechnol 93(2):601–611. doi:10.1007/s00253-011-3569-8

    Article  CAS  Google Scholar 

  • Shaw G, Morse S, Ararat M, Graham FL (2002) Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J Off Publ Fed Am Soc Exp Biol 16(8):869–871. doi:10.1096/fj.01-0995fje

    CAS  Google Scholar 

  • Tobita K, Tanaka T, Hayase Y (1997) Rescue of a viral gene from Vero cells latently infected with influenza virus B/Lee/40. Virology 236(1):130–136

    Article  CAS  Google Scholar 

  • Tseng YF, Hu AY, Huang ML, Yeh WZ, Weng TC, Chen YS, Chong P, Lee MS (2011) Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness. PLoS One 6(10):e24057. doi:10.1371/journal.pone.0024057

    Article  CAS  Google Scholar 

  • van Wielink R, Kant-Eenbergen HC, Harmsen MM, Martens DE, Wijffels RH, Coco-Martin JM (2011) Adaptation of a Madin-Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines. J Virol Methods 171(1):53–60. doi:10.1016/j.jviromet.2010.09.029

    Article  Google Scholar 

  • Vester D, Rapp E, Gade D, Genzel Y, Reichl U (2009) Quantitative analysis of cellular proteome alterations in human influenza A virus-infected mammalian cell lines. Proteomics. doi:10.1002/pmic.200800893

  • Vester D, Rapp E, Kluge S, Genzel Y, Reichl U (2010) Virus–host cell interactions in vaccine production cell lines infected with different human influenza A virus variants: a proteomic approach. J Proteomics 73(9):1656–1669. doi:10.1016/j.jprot.2010.04.006

    Article  CAS  Google Scholar 

  • Von Magnus P (1954) Incomplete forms of influenza virus. Adv Virus Res 2:59–79

    Article  Google Scholar 

  • Zhirnov OP, Vorobjeva IV, Saphonova OA, Poyarkov SV, Ovcharenko AV, Anhlan D, Malyshev NA (2009) Structural and evolutionary characteristics of HA, NA, NS and M genes of clinical influenza A/H3N2 viruses passaged in human and canine cells. J Clin Virol 45(4):322–333. doi:10.1016/j.jcv.2009.05.030

    Article  CAS  Google Scholar 

Download references

Acknowledgment

The authors would like to thank V. Lohr for critical proof reading of the manuscript.

Author information

Authors and Affiliations

  1. Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Sandtorstr. 1, 39106, Magdeburg, Germany

    Yvonne Genzel, Ilona Behrendt, Jana Rödig, Erdmann Rapp & Udo Reichl

  2. Department of Gene Therapy, University of Ulm, Helmholtzstr. 8/1, 89081, Ulm, Germany

    Claudia Kueppers & Stefan Kochanek

  3. CEVEC Pharmaceuticals GmbH, Gottfried-Hagen-Str. 62, 51105, Cologne, Germany

    Gudrun Schiedner

  4. Chair for Bioprocess Engineering, Otto-von-Guericke-University Magdeburg, Universitätsplatz 2, 39106, Magdeburg, Germany

    Udo Reichl

Authors
  1. Yvonne Genzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ilona Behrendt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jana Rödig
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Erdmann Rapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claudia Kueppers
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stefan Kochanek
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gudrun Schiedner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Udo Reichl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yvonne Genzel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Genzel, Y., Behrendt, I., Rödig, J. et al. CAP, a new human suspension cell line for influenza virus production. Appl Microbiol Biotechnol 97, 111–122 (2013). https://doi.org/10.1007/s00253-012-4238-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00253-012-4238-2

Keywords

Search

Navigation